Immunoglobulin News and Research

RSS

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

A recent study explored the safety, immunogenicity, and VE of the SARS-CoV-2 mRNA BNT162b2 and mRNA1273 vaccines against its Omicron VOC in HCWs in Israel.

18 Feb 2022

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

Researchers recently assessed SARS-CoV-2-specific humoral and cellular immune responses induced by the second and third doses of the BNT162b2 COVID-19 messenger ribonucleic acid-based vaccine in the elderly.

17 Feb 2022

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

New study findings reveal that the level of afucosylated anti-spike antibodies increases transiently in infection-naïve individuals after the first COVID-19 vaccine dose.

17 Feb 2022

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

Researchers examined the memory B cell repertoire of individuals immunized with three doses of mRNA-based COVID-19 vaccine.

17 Feb 2022

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

A new study examines neutralizing responses to the ancestral variant of SARS-CoV-2, as well as against later variants of concern.

16 Feb 2022

Features of platelet-immune crosstalk in healthy recipients of two doses of mRNA-based SARS-CoV-2 vaccine BNT162b2

Researchers investigated the role of platelets in the adverse immune response against a COVID-19 vaccine.

16 Feb 2022

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Researchers study antibodies against various SARS-CoV-2 epitopes that may be responsible for neutralizing activities in recovered COVID-19 patients.

15 Feb 2022

Canadian study estimates incidence rate of reinfection in healthcare workers

Researchers from various Canadian institutions document all cases of reinfection discovered during the first year of the project.

15 Feb 2022

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

In a new study, researchers investigated whether neutralizing antibodies against the SARS-CoV-2 spike protein offered adequate immunity against breakthrough infections among vaccinated individuals.

15 Feb 2022

Real-world data on efficacy and safety of COVID vaccines in Canada

In a recent study posted to the medRxiv* preprint server, researchers evaluated the efficacy and safety of the coronavirus disease 2019 (COVID-19) vaccines in young and elderly cohorts from Canada.

14 Feb 2022

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

A recent study demonstrated that intranasal (i.n.) delivery of COVID-19 vaccine in murine models elicits greater immune responses against the wildtype SARS-CoV-2 and its variants.

14 Feb 2022

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

Researchers tested convalescent sera from individuals who had recovered from SARS-CoV-2 infection to demonstrate an association between antibody response and reported COVID-19 symptoms.

14 Feb 2022

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

A new study was based on the hypothesis that competitively inhibiting cellular furin and selectively targeting SARS-CoV-2 in the infected viral-producing cells is critical for therapeutic specificity.

14 Feb 2022

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

A recent paper by researchers from Australia, currently available on the medRxiv* preprint server, shows how Immunoglobulin A (IgA) antibodies in individuals who were infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contribute to the neutralization of the virus and its variants, even though this response is heterogeneous and less potent when compared to IgG antibodies.

13 Feb 2022

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

A new study compares antibody levels in newborns born from mothers vaccinated against COVID-19 and to maternal infection with SARS-CoV-2.

9 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

Exploring omicron infection in COVID-19 vaccinated and convalescent South African healthcare workers

In a new study, researchers evaluated healthcare workers in South Africa, presenting with SARS-CoV-2 symptoms, for infection by the Omicron variant.

9 Feb 2022

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

Researchers investigated the dynamics and longevity of neutralizing antibody response up to 480 days after the onset of infection in convalescent COVID-19 patients.

9 Feb 2022

The B and T cell responses to SARS-CoV-2

Researchers assess the correlation between humoral and cell-mediated responses to SARS-CoV-2 in symptomatic and asymptomatic individuals.

8 Feb 2022

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

In a recent research article published in the journal of Science Immunology, a team of researchers from Japan performed longitudinal analysis on the cellular composition of receptor-binding domain (RBD) memory B cell subsets and its antibody binding and neutralizing activity against the Beta, Delta, and Omicron variants following the second dose of a messenger ribonucleic acid (mRNA) vaccine.

8 Feb 2022

Immunoglobulin News and Research

Immunogenicity, efficacy, and safety of BNT162b2 or mRNA1273 fourth dose

Study explores humoral and cellular immunity conferred by second and third COVID-19 BNT162b2 vaccination in elderly

mRNA COVID-19 vaccine shown to induce afucosylated antibodies in individuals without prior SARS-CoV-2 exposure

Memory B cell repertoire in a longitudinal cohort of individuals receiving 3 COVID-19 mRNA vaccine doses

Children with severe COVID-19 show low mucosal neutralizing activity against SARS-CoV-2

Features of platelet-immune crosstalk in healthy recipients of two doses of mRNA-based SARS-CoV-2 vaccine BNT162b2

Neutralizing antibody levels to different SARS-CoV-2 epitopes fluctuate over time

Canadian study estimates incidence rate of reinfection in healthcare workers

Post-vaccination titers of neutralizing antibodies revealed as a moderate predictor of vaccine-induced immunity

Real-world data on efficacy and safety of COVID vaccines in Canada

Development of multivalent next-generation vaccine strategy against ancestral SARS-CoV-2 and emerging variants

Study demonstrates associations between COVID-19 symptom presentation and antibody assay reactivity

An alternative strategy targeting furin disrupts SARS-CoV-2 infection cycle

Study shows IgA antibodies play a significant role in neutralizing SARS-CoV-2

Newborn antibodies following maternal COVID-19 vaccination persist for up to six months

How SARS-CoV-2 infection progresses throughout the respiratory system

Exploring omicron infection in COVID-19 vaccinated and convalescent South African healthcare workers

Dynamics and longevity of antibody response from COVID-19 convalescents across the clinical spectrum

The B and T cell responses to SARS-CoV-2

Memory B cells induced by mRNA vaccine may help generate antibodies against Omicron

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Discover how SciY empowers scientists

Latest News